Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

Cancer Cell. 2018 Feb 12;33(2):155-157. doi: 10.1016/j.ccell.2018.01.015.


The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.

Publication types

  • Comment

MeSH terms

  • B7-H1 Antigen*
  • Humans
  • Immunotherapy
  • Polysaccharides
  • Triple Negative Breast Neoplasms*


  • B7-H1 Antigen
  • Polysaccharides